Mostrar el registro sencillo del ítem

Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease?

dc.contributor.authorMohajeri M.
dc.contributor.authorBehnam B.
dc.contributor.authorBarreto G.E.
dc.contributor.authorSahebkar A.
dc.date.accessioned2020-09-02T22:23:03Z
dc.date.available2020-09-02T22:23:03Z
dc.date.issued2019
dc.identifier10.1016/j.phrs.2019.03.023
dc.identifier.citation143, , 186-203
dc.identifier.issn10436618
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5353
dc.descriptionCarbon-based nanomaterials have unique physicochemical properties relevant to the diagnosis and treatment of various diseases. There have been many reports indicating that carbon nanomaterials (CNMs) can interact and perturb biomolecules such as proteins and amyloid structures. This review is an attempt to reflect the role of CNMs in the treatment and detection of Alzheimer's disease (AD). The potential of CNMs in the field of neuroscience has also been reviewed. The exposure to CNMs ends up with effective radical and peptide scavenging structures, which, in turn, inhibit further formation and progression of amyloid fibrils. However, the effect of CNMs on initial nucleation and lag phase in this process may promote fibrillation. We have discussed the controversy that whether CNMs promote or inhibit the formation of amyloid beta (Aβ) fibrils to help preventing their toxicity or enhancing their therapeutic effects. © 2019 Elsevier Ltd
dc.language.isoen
dc.publisherAcademic Press
dc.subjectAlzheimer's disease
dc.subjectAmyloid beta fibril
dc.subjectCarbon nanomaterials
dc.subjectToxicity
dc.subjectamyloid beta protein
dc.subjectamyloid precursor protein
dc.subjectbiological marker
dc.subjectcarbon nanomaterial
dc.subjectcholinesterase inhibitor
dc.subjectdonepezil
dc.subjectfluorodeoxyglucose f 18
dc.subjectflutemetamol f 18
dc.subjectfullerene
dc.subjectgalantamine
dc.subjectgraphene
dc.subjectnanomaterial
dc.subjectrivastigmine
dc.subjecttacrine
dc.subjectunclassified drug
dc.subjectamyloid beta protein
dc.subjectcarbon
dc.subjectnanomaterial
dc.subjectAlzheimer disease
dc.subjectdrug delivery system
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug exposure
dc.subjectdrug mechanism
dc.subjectgenetic association
dc.subjecthuman
dc.subjectlimit of detection
dc.subjectlimit of quantitation
dc.subjectnear infrared spectroscopy
dc.subjectnonhuman
dc.subjectnuclear magnetic resonance imaging
dc.subjectphysical chemistry
dc.subjectpositron emission tomography
dc.subjectpriority journal
dc.subjectprotein aggregation
dc.subjectprotein function
dc.subjectprotein interaction
dc.subjectprotein secretion
dc.subjectprotein structure
dc.subjectReview
dc.subjectanimal
dc.subjectgenetic procedures
dc.subjectmetabolism
dc.subjectAlzheimer Disease
dc.subjectAmyloid beta-Peptides
dc.subjectAnimals
dc.subjectBiosensing Techniques
dc.subjectCarbon
dc.subjectHumans
dc.subjectNanostructures
dc.titleCarbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease?
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85063760662.pdf
Tamaño:
3.301Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem